Relmada Therapeutics Inc
NASDAQ:RLMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
RLMD's latest stock split occurred on Sep 30, 2019
The company executed a 1-for-4 stock split, meaning that for every 4 shares held, investors received 1 new share.
Before the split, RLMD traded at 2.6 per share. Afterward, the share price was about 10.25.
The adjusted shares began trading on Sep 30, 2019. This was RLMD's 2nd stock split, following the previous one in Aug 12, 2015.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 17, 2026
|
M
|
Miwon Chemicals Co Ltd
KRX:134380
|
10-for-1
x10
|
147900 14790 KRW | 13550 13550 KRW |
|
Apr 17, 2026
|
S
|
Shenzhen Best of Best Holdings Co Ltd
SZSE:001298
|
1-for-1
x1
|
30.47 20.9438 CNY | 21.98 21.98 CNY |
|
Apr 17, 2026
|
T
|
Thanh Thanh Cong - Bien Hoa JSC
VN:SBT
|
53-for-50
x1.06
|
21899.9941 20660.3718 VND | 20650 20650 VND |
|
Apr 17, 2026
|
P
|
Pt Harta Djaya Karya Tbk
IDX:MEJA
|
7-for-6
x1.1666666666667
|
118.0001 101.1429 IDR | 111 111 IDR |
|
Apr 17, 2026
|
|
Yesco Holdings Co Ltd
KRX:015360
|
5-for-1
x5
|
80000 16000 KRW | 16110 16110 KRW |
015360
Relmada Therapeutics Inc
Glance View
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Coral Gables, Florida and currently employs 10 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).
